{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:41:05Z","timestamp":1781880065053,"version":"3.54.5"},"reference-count":40,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2012,9,11]],"date-time":"2012-09-11T00:00:00Z","timestamp":1347321600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mantle cell lymphoma (MCL) is a subtype of B\u2010cell Non\u2010Hodgkin's Lymphoma (NHL) and accounts for \u223c6% of all lymphomas. MCL is highly refractory to most chemotherapy including newer antibody\u2010based therapeutic approaches, and high\u2010grade MCL has one of the worst survival rates among NHLs. Therefore, the development of new therapeutic strategies to overcome drug resistance of MCL is important. In this article, we tested the effects of arsenic trioxide (As<jats:sub>2<\/jats:sub>O<jats:sub>3<\/jats:sub>, ATO) in bortezomib\u2010resistant MCL. ATO is reported to induce complete remission in the patients with relapsed or refractory acute promyelocytic leukemia. Their effects in MCL, however, have not been explored. In this report, we show that ATO effectively inhibited the growth of MCL cells in vitro. ATO treatment also reduced cyclin D1 expression which is a genetic hallmark of MCL and NF\u2010kB expression which was reported to have a prosurvival role in some MCL cells. The induction of apoptosis in MCL was partially due to reduced levels of cyclin D1 and increased levels of apoptosis\u2010related molecules. The antiproliferative effects of bortezomib on MCL greatly increased when the cells were also treated with ATO, indicating ATO can sensitize MCL to bortezomib. Similar results were noted in bortezomib\u2010resistant cell lines. In conclusion, ATO may be an alternative drug for use in combined adjuvant therapies for MCL, and further clinical testing should be performed. Am. J. Hematol., 2012. \u00a9 2012 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.23317","type":"journal-article","created":{"date-parts":[[2012,8,3]],"date-time":"2012-08-03T18:00:34Z","timestamp":1344016834000},"page":"1057-1064","source":"Crossref","is-referenced-by-count":19,"title":["Synergistic anticancer effects of arsenic trioxide with bortezomib in mantle cell lymphoma"],"prefix":"10.1002","volume":"87","author":[{"given":"Hyun Joo","family":"Jung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nami","family":"McCarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,9,11]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.75.879.2"},{"key":"e_1_2_7_3_2","first-page":"11","article-title":"Mantle cell lymphoma: From pathology and molecular pathogenesis to new therapeutic perspectives","volume":"91","author":"Salaverria I","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.013359"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.2174\/138920106779116829"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.10.217"},{"key":"e_1_2_7_7_2","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1182\/blood.V88.3.1052.1052","article-title":"In vitro studies on cellular and molecular mechanisms of arsenic trixoide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl\u20102 expression and modulation of PML\u2010RAR alpha\/PML proteins","volume":"88","author":"Chen GQ","year":"1996","journal-title":"Blood"},{"key":"e_1_2_7_8_2","first-page":"19","article-title":"Treatment of acute granulocytic leukemia with Ai ling No. 1: Clinical analysis and experiment research","volume":"4","author":"Zhang TD","year":"1984","journal-title":"Chin J Comb Trad West Med"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2009.04.007"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402599"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.04941.x"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403419"},{"key":"e_1_2_7_13_2","first-page":"3893","article-title":"Mechanisms of action of arsenic trioxide","volume":"62","author":"Miller WH","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02787360"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.2174\/1389201023378265"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401112"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.1.88"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2011.10.004"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190801910912"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.scr.2010.07.003"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1124\/pr.58.3.10"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.767"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/371346a0"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(95)90541-3"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.40.28379"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07284.x"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gde.2008.01.020"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.8.2301"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.6-suppl_2-1"},{"key":"e_1_2_7_30_2","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1182\/blood.V89.9.3354","article-title":"Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL). II. Clinical efficacy and pharmacokinetics in relaspsed patients","volume":"89","author":"Shen ZX","year":"1997","journal-title":"Blood"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-107839"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.01.149"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.5.1701"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2005.07.125"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI42874"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0b013e3283257aee"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2571(99)00024-2"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006962716377"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2009.05.024"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404735"},{"key":"e_1_2_7_41_2","first-page":"909","article-title":"Effect of arsenic trioxide on induction of apoptosis in MCL cell line and its possible mechanisms","volume":"18","author":"Fei AM","year":"2010","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.23317","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.23317","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T20:43:53Z","timestamp":1697057033000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.23317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,11]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["10.1002\/ajh.23317"],"URL":"https:\/\/doi.org\/10.1002\/ajh.23317","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,11]]}}}